

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/05	A1	(11) International Publication Number: WO 00/06142 (43) International Publication Date: 10 February 2000 (10.02.00)
(21) International Application Number: PCT/US99/17433 (22) International Filing Date: 30 July 1999 (30.07.99) (30) Priority Data: 09/127,082 31 July 1998 (31.07.98) US (71) Applicant: VETERINARY RESEARCH ASSOCIATES [US/US]; 20 Old Dock Road, Yaphank, NY 11960 (US). (72) Inventor: KOMER, Gene; 2817 West County Road 54G, Fort Collins, CO 80524 (US). (74) Agents: GREENLEE, Lorraine, L. et al.; Greenlee, Winner and Sullivan, P.C., Suite 201, 5370 Manhattan Circle, Boulder, CO 80303 (US).		(81) Designated States: AU, CA, JP, MX, NZ, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: INJECTABLE PROPOFOL FORMULATIONS (57) Abstract The invention provides injectable formulations of propofol using N-methylpyrrolidone or 2-pyrrolidone as a solvent. Formulations of the invention are useful in all medical and veterinary indications when propofol is presently used. In addition, combinations of propofol and an appropriate toxin are useful for fast-acting, humane, veterinary euthanasia injectable compositions. N-methylpyrrolidone-propylene glycol formulations are inherently bacteriostatic, thereby eliminating one of the problems associated with currently available formulations.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INJECTABLE PROPOFOL FORMULATIONS

Propofol is a quick-acting anesthetic of short duration marketed for human anesthesia under the trade name *Diprivan* by Stuart Pharmaceuticals and marketed for anesthesia in dogs by Schering-Plough Animal Health Corporation under the trade name *Rapinovel* and by
5 Abbott Laboratories under the trade name *PropoFlo*.

Propofol is poorly soluble in water. The early human product was solubilized in a surfactant known as Cremophor EL. There were many instances of allergic reactions to the surfactant, requiring that the product be reformulated. At present all three propofol products are marketed as a cloudy emulsion of soybean oil, lecithin and other minor ingredients.

10 The currently available product contains no antimicrobial preservatives, making it particularly susceptible to microbial contamination after opening because of the nutrient base. Major problems associated with infections in patients anesthetized with propofol have been reported. Stuart Pharmaceuticals sent a "Dear Doctor" letter to anesthesiologists in 1990 addressing the post-operative incidence of fevers and infections in patients anesthetized with
15 Diprivan. An additional problem has been encountered with the use of sterile glass ampoules for packaging propofol suspensions. Occasionally, glass particles contaminate the suspension after the ampoule is cracked open, leading to the inconvenient necessity of filtering the suspension prior to injection.

20 Propofol is 2,6-diisopropylphenol. It is an extremely fast-acting anaesthetic of short duration, administered intravenously. Its medical and veterinary use is primarily for rapid anesthesia, often in conjunction with slower-onset anesthetics, and for procedures of short

duration. Maximum solubility in water is reported as $1.0 \pm 0.02 \mu\text{M}$ at 22.5°C ; Tonner, P.H. et al. (1992) *Anesthesiology* 77:926-931. Currently, only the soybean oil suspension of propofol is available in the market, despite the disadvantages thereof, which have been known for many years.

5 N-methylpyrrolidone and 2-pyrrolidone have not been widely used in the formulation of injectable medicaments. U.S. Patent 4,772,460 discloses the use of N-methylpyrrolidone for parenteral administration of oxytetracycline. U.S. Patent 5,707,996 describes solubilization of trimethoprim and sulfadiazine. The antibiotic florfenicol is marketed as an injectable formulation in N-methylpyrrolidone, propylene glycol and polyethylene glycol for
10 intramuscular injection in cattle.

SUMMARY OF THE INVENTION

The invention provides injectable formulations of propofol using N-methylpyrrolidone or 2-pyrrolidone as a solvent. Formulations of the invention can include other components including other pharmacologic agents, diluents, co-solvents, expanders,
15 dispersants, surface-active agents and the like, as will be understood by those skilled in the formulation art and as appropriate for the active ingredients of the formulation. Formulations of the invention are useful in all medical and veterinary indications when propofol is presently used. In addition, combinations of propofol and an appropriate toxin are useful for fast-acting, humane, veterinary euthanasia injectable compositions. N-methylpyrrolidone-
20 propylene glycol formulations are inherently bacteriostatic, thereby eliminating one of the problems associated with currently available formulations.

DETAILED DESCRIPTION OF THE INVENTION

The solubilization of propofol in N-methylpyrrolidone and other physiologically acceptable co-solvents such as propylene glycol and water provides significant advantages in
25 the manufacture, use, pharmaceutical elegance and stability of propofol injectable products. Not only is the N-methylpyrrolidone-propofol product water clear, it does not provide a nutrient base for microbial growth. In fact, N-methylpyrrolidone-propylene glycol mixtures are bacteriostatic.

Propofol formulations have been found to be completely stable for at least 32 months storage at room temperature.

The present invention is not only superior for propofol anesthesia injectables, but also for making a veterinary euthanasia injectable composition. The 1993 AVMA Panel on Euthanasia recommended use of barbiturates such as pentobarbital for small animal euthanasia. The barbiturates are narcotic controlled drugs regulated by the DEA. There is considerable paperwork involved as well as having many record-keeping and security requirements such as a locked safe. Propofol provides rapid onset of anesthesia so that an animal to be euthanized experiences minimal discomfort as the lethal effects of the euthanizing toxin take hold. The combination is more humane than previously approved formulations, such as T-61, which have been shown, in some instances, to afford a period of consciousness even as respiratory depression is occurring. A preferred composition for euthanizing purposes includes propofol and a curariform agent.

Formulations of propofol in N-methylpyrrolidone, 2-pyrrolidone, or mixtures thereof, can contain from 1% to 20% (w/v) propofol. Therapeutic dosage is well-known in the art, usually delivered at 10-20 mg propofol/ml. The ability to provide a more concentrated formulation has several advantages. The anesthetic can be delivered in a smaller volume. Any side effects due to other formulation components can be minimized. If desired, a larger amount of the anesthetic can be delivered in a single dose.

A formulation of the invention can simply be propofol dissolved in N-methylpyrrolidone, 2-pyrrolidone, or mixtures thereof. Other formulations can include propylene glycol or other non-toxic polyhydroxy alcohols, including, e.g., polyethylene glycol. Such formulations can contain up to 90% (v/v) propylene glycol or other non-toxic polyhydroxy alcohol as a diluent. N-methylpyrrolidone, 2-pyrrolidone or a mixture thereof can constitute as little as 5% (w/v). The formulations of the invention can include water, quantum sufficit (q.s.) up to 50% (v/v).

Preferred euthanizing formulations include propofol in combination with a skeletal muscle relaxant, capable of inhibiting muscle contraction. Suitable muscle relaxants include succinylcholine chloride, gallamine and curariform agents, such as mivacurium, atracurium, cisatracurium, vecuronium, rocuronium, pancuronium, metocurine, tubocurarine, doxycurium, 5 pipecuronium, and suitable salts thereof, as well as other inhibitors of muscle contraction acting at the neuromuscular junction.

Optional ingredients include a local anesthetic agent of the type well-known in the art, e.g., lidocaine, and a preservative of a type well-known in the art, such as benzyl alcohol. Examples of suitable formulations are as follows.

10 Example 1: Anesthesia Formulation #1

Propofol	10 mg/ml
N-Methylpyrrolidone	30% w/v
Propylene Glycol	40% w/v
Water for Injection, qs	~31% v/v

15 Example 2: Anesthesia Formulation #2

Propofol	20 mg/ml
N-Methylpyrrolidone	30% w/v
Propylene Glycol	40% w/v
Water for Injection, qs	~30% v/v

20 Example 3: Euthanasia Formulation #1

Propofol	10 mg/ml
Succinylcholine chloride	20 mg/ml
Lidocaine HCl	20 mg/ml
N-Methylpyrrolidone	30% w/v
25 Propylene Glycol	40% w/v
Benzyl Alcohol	1.5% v/v
Purified Water	qs

Example 4: Euthanasia Formulation #2

	Propofol	10 mg/ml
	Pancuronium Bromide	2 mg/ml
	Lidocaine	20 mg/ml
5	N-Methylpyrrolidone	40% w/v
	Propylene Glycol	30% w/v
	Benzyl Alcohol	2% v/v
	Purified Water	qs

CLAIMS

I claim:

1. An injectable anesthetic formulation comprising propofol and N-methyl pyrrolidone, or 2-pyrrolidone, or a mixture thereof.
2. The formulation of claim 1 wherein the propofol concentration is 1% - 20% w/v.
3. The formulation of claim 1 further comprising a non-toxic polyhydroxy alcohol.
4. The formulation of claim 3 wherein the polyhydroxy alcohol is propylene glycol.
5. The formulation of claim 4 comprising up to 90% (v/v) propylene glycol.
6. The formulation of claim 3 wherein the polyhydroxy alcohol is polyethylene glycol.
7. The formulation of claim 3 further comprising water.
8. A formulation according to claim 7 having the composition: propofol, 10 mg/ml; N-methylpyrrolidone 30% (w/v), propylene glycol 40% w/v and water quantum sufficit.
9. A formulation according to claim 7 having the composition: Propofol, 20 mg/ml; N-methylpyrrolidone 30% (w/v); propylene glycol, 40% (w/v) and water quantum sufficit.
10. A formulation for veterinary euthanasia comprising propofol, a skeletal muscle relaxant and N-methyl pyrrolidone, 2-pyrrolidone or a mixture thereof.
11. The formulation of claim 10 wherein the propofol concentration is 1% - 20% w/v.
12. The formulation of claim 10 further comprising a non-toxic polyhydroxy alcohol.

13. The formulation of claim 12 wherein the polyhydroxy alcohol is propylene glycol.
14. The formulation of claim 13 comprising up to 90% (v/v) propylene glycol.
15. The formulation of claim 12 wherein the polyhydroxy alcohol is polyethylene glycol.
16. The formulation of claim 12 further comprising water.
17. A formulation according to claim 10 wherein the skeletal muscle relaxant is selected from the group consisting of succinyl, choline chloride, gallamine, miracurium, atracurium, cisatracurium, vecuronium, rocuronium, pancuronium, metocurine, tubocurarine, doxycurium, pipecuronium, and suitable salts thereof.
18. A formulation according to claim 16 having the composition: propofol 10 mg/ml; succinylcholine chloride, 20 mg/ml; lidocaine HCl, 20 mg/ml, N-methylpyrrolidone, 30% (w/v); propylene glycol, 40% (w/v); benzyl alcohol, 1.5% v/v; and water, quantum sufficit.
19. A formulation according to claim 16 having the composition: propofol, 10 mg/ml; pancuronium bromide, 2 mg/ml; lidocaine, 20 mg/ml; N-methylpyrrolidone, 40% (w/v); propylene glycol, 30% (w/v); benzyl alcohol, 2% v/v; and water, quantum sufficit.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/17433

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :A61K 31/05 US CL :514/731 According to International Patent Classification (IPC) or to both national classification and IPC														
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/731 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)														
C. DOCUMENTS CONSIDERED TO BE RELEVANT														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
A	US 5,446,070 A (MANTELLE) 29 AUGUST 1995(29/8/95).	1-19												
A	US 5,496,537 A (HENRY) 05 March 1996(5/3/96).	1-19												
A	US 5,707, 996 A (PARRINELLO) 13 January 1998(13/1/98).	1-19												
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"E" earlier document published on or after the international filing date</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td></td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family	"O" document referring to an oral disclosure, use, exhibition or other means		"P" document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family													
"O" document referring to an oral disclosure, use, exhibition or other means														
"P" document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search		Date of mailing of the international search report												
05 OCTOBER 1999		06 DEC 1999												
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer RAYMOND J. HENLEY III Telephone No. (703) 308-1235												